CARANX-MEDICAL
16.4.2024 10:31:35 CEST | Business Wire | Press release
Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal.
The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team.
“This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx.
“This major medical first lies not only in the technical achievement of Caranx Medical's engineers, but also in the impact that this technology will have on interventional cardiology practice. By simplifying and standardizing a complex procedure, the robot we have developed opens up new possibilities for improving the performance and safety of TAVI procedures” says Dr. Eric Sejor, co-founder and CMO of Caranx.
The TAVI procedure was introduced app. 20 years ago, and still critical challenges and long learning curves are faced by cardiologists during these procedures in a precise and accurate delivery of the heart valve. This is resulting in only 300.000 TAVI procedures being conducted annually in the USA and EU, despite over 1.700.000 eligible patients and the difficulty of the procedure still triggers some drawbacks like frequent need for post procedure pacemakers, due to a lack of precision in the delivery of the implant.
"It is with logic that we prove, and with intuition that we find". “This quote from Henri Poincaré perfectly sums up the work of the Caranx team, who had the intuition, that robotics combined with artificial intelligence and imaging could improve the results of prosthetic heart valve implantation. During this first robotic implantation on a porcine model, the sensations were very similar to those observed during a conventional procedure on our patients. There is no doubt that the use of robotics coupled with artificial intelligence and imaging will improve the safety, precision and reproducibility of the procedure in humans” says Dr. Stéphane Lopez, Institut Arnault Tzanck, Saint Laurent du var, France, who performs more than 400 TAVI procedures per year.
“The team at Caranx, has achieved an important milestone as it successfully deployed a balloon-expandable device in the aortic position, in a pig model. This extremely promising step paves the way to a first-in-human utilization. I am very excited about robotic-assisted TAVI/TAVR, a key to the harmonization of practices as well as the promotion of more predictable and controlled valve deployment. Our patients will undoubtedly benefit from this breakthrough technology in the future” says Dr. Didier Tchétché, Clinique Pasteur, Toulouse, France, who performs more than 1.000 TAVI procedures per year.
According to Frost and Sullivan, the TAVI market is an $8Bn market growing double digits annually.
“With Caranx impressive technology and team, interventional cardiology and physicians can hope for what aircrafts and pilots have been benefiting from for decades: reliable automation, supervised by pilots, imaging and AI for medicine mimicking satellite/GPS systems for flying” says Dr. Philippe Pouletty, co-founder of Caranx and CEO of Truffle Capital.
The Caranx Medical robotic solution, TAVI-PILOT, is a simple, easy-to-use robotic solution, which promises precise, accurate and autonomous valve positioning and delivery. TAVI-PILOT is a revolution for the replacement of the aortic valve, which is restricted because it is reserved for the most experienced cardiologists. Like soft tissue robots have multiplied the number of urologists comfortable to execute a mini-invasive surgical removal of the prostate, TAVI-PILOT will multiply the number of interventional cardiologists to perform safely this life saving procedure.
“This is a major achievement by the Caranx team in the past months. However, at Caranx Medical, we're not just stopping at Aortic valve replacement. Our vision extends to developing our Artificial Intelligence Platform, currently containing more than 5000 of annotated multimodality images of CT, Fluoroscopy, Echo, reports, etc. used to feed our AI algorithms and to revolutionize other endovascular indications, such as mitral and tricuspid valve replacements or even other endoluminal procedures, reshaping the landscape of interventional medicine” says CEO of Caranx, Jorgen Hansen.
About Caranx Medical
Backed by a team of top-tier experts, management team and supported by Truffle Capital, a renowned name in European biotech and MedTech investment, Caranx Medical is a French MedTech company, founded by CMO Dr. Eric Sejor, CTO Pierre Berthet-Rayne, PhD. and Dr. Philippe Pouletty and Truffle Capital, with the ambition to become a global leader in robotic assisted transcatheter heart valve implantation.
Caranx Medical develops the TAVI PILOT, a simple, easy-to-use robotic solution, which promises precise, accurate and autonomous valve positioning and delivery. Caranx Medical’s strategy includes bringing to market TAVI PILOT Soft, an AI intra-operative GPS software which tracks real-time anatomical and instrument landmarks on fluoroscopic images and TAVI PILOT Robotic solution to First in Human in 2025.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416108426/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom